Metrics as of 10/13/2026, 06:55 PM (Berlin time), refresh in progress.
Sutro Biopharma Stock
Sutro Biopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jane Chung
- Employees
- 128
- Market cap
- $109 M
- IPO
- 27/09/2018
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its…
Sutro Biopharma stock: price history
1D
-14.6%
1W
-21.5%
1M
-32.7%
6M
-60.6%
YTD
-1.9%
1Y
+37.0%
2Y
-70.1%
5Y
-93.9%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~30% stronger price swings than usual
Ask the agents about Sutro Biopharma
Analyst assessment of Sutro Biopharma
PRICE TARGET LOW
US$43.00
CONSENSUS
US$51.00
MEDIAN
US$50.00
PRICE TARGET HIGH
US$60.00
0
STRONG BUY
18
BUY
1
HOLD
1
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 13/08/2026
Sutro Biopharma stock metrics
P/E
-0.65
P/B
-1.8
EV/EBITDA
-0.48
RETURN ON EQUITY
37.3%
NET MARGIN
-391.6%
DEBT/EQUITY
-0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
70.6%
FLOAT SHARES
6,829,763
AVG. DAILY VOLUME (30D)
300,774
Insider transactions (SEC)
Gerber Hans-Peter
Gerber Hans-Peter
Chow Gregory K.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Sutro Biopharma stock
What does Sutro Biopharma do?
Sutro Biopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jane Chung, the company employs around 128 people.
The IPO was on 27/09/2018; the stock trades on NASDAQ under the ticker STRO.
What do analysts say about Sutro Biopharma stock?
20 analysts rate the stock, the consensus is Buy (as of 13/08/2026).
The average price target is US$51.00, ranging from US$43.00 to US$60.00, with a median of US$50.00.
This is an external assessment, not a statement by Market Jury.
When does Sutro Biopharma report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 30% stronger than usual.
Does Sutro Biopharma pay a dividend?
No, Sutro Biopharma currently does not pay a dividend.
Which stocks are comparable to Sutro Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Sutro Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sutro Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.